IRIS
ROTTOLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.214
EU - Europa 14.404
AS - Asia 7.570
SA - Sud America 1.295
AF - Africa 332
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 16
Totale 40.868
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.934
GB - Regno Unito 3.125
CN - Cina 2.746
RU - Federazione Russa 2.618
SG - Singapore 2.113
IT - Italia 2.074
IE - Irlanda 1.890
UA - Ucraina 1.071
BR - Brasile 1.064
SE - Svezia 951
FR - Francia 927
VN - Vietnam 848
DE - Germania 784
HK - Hong Kong 627
FI - Finlandia 445
KR - Corea 345
IN - India 234
CA - Canada 169
ZA - Sudafrica 136
ES - Italia 111
TR - Turchia 105
BD - Bangladesh 93
AR - Argentina 88
JP - Giappone 88
PL - Polonia 75
NG - Nigeria 69
NL - Olanda 67
MX - Messico 65
IQ - Iraq 64
BE - Belgio 53
CZ - Repubblica Ceca 51
ID - Indonesia 34
PK - Pakistan 34
AT - Austria 32
AU - Australia 32
UZ - Uzbekistan 30
CO - Colombia 28
MA - Marocco 28
SA - Arabia Saudita 28
EC - Ecuador 27
CI - Costa d'Avorio 26
VE - Venezuela 22
IL - Israele 18
KE - Kenya 18
LT - Lituania 18
CL - Cile 17
PY - Paraguay 17
AZ - Azerbaigian 15
PH - Filippine 15
IR - Iran 14
JM - Giamaica 14
PT - Portogallo 14
RO - Romania 14
GR - Grecia 12
JO - Giordania 12
TN - Tunisia 12
UY - Uruguay 12
KG - Kirghizistan 11
KZ - Kazakistan 11
MY - Malesia 11
PE - Perù 11
AE - Emirati Arabi Uniti 10
EG - Egitto 10
EU - Europa 10
DZ - Algeria 9
CH - Svizzera 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
ET - Etiopia 7
NP - Nepal 7
EE - Estonia 6
HU - Ungheria 6
LU - Lussemburgo 6
CR - Costa Rica 5
CY - Cipro 5
DK - Danimarca 5
LB - Libano 5
LV - Lettonia 5
PA - Panama 5
XK - ???statistics.table.value.countryCode.XK??? 5
BB - Barbados 4
DO - Repubblica Dominicana 4
KW - Kuwait 4
LK - Sri Lanka 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
AM - Armenia 3
AO - Angola 3
BY - Bielorussia 3
GE - Georgia 3
HN - Honduras 3
LA - Repubblica Popolare Democratica del Laos 3
QA - Qatar 3
SC - Seychelles 3
SN - Senegal 3
SY - Repubblica araba siriana 3
Totale 40.818
Salva come PNG Salva come JPEG
Città #
Southend 2.703
Dublin 1.881
Dallas 1.833
Fairfield 1.793
Singapore 1.229
Ashburn 1.160
Chandler 1.143
Houston 897
Jacksonville 862
Woodbridge 782
Beijing 711
Moscow 710
Santa Clara 705
Seattle 650
Wilmington 599
Hong Kong 591
Cambridge 533
San Jose 503
Ann Arbor 466
Siena 416
Princeton 361
Hefei 334
Seoul 308
The Dalles 278
Nanjing 273
Los Angeles 247
Ho Chi Minh City 240
New York 230
Helsinki 226
Lauterbourg 194
Hanoi 181
Council Bluffs 176
Munich 158
Menlo Park 151
Boardman 146
Dearborn 119
Johannesburg 119
Nanchang 117
Buffalo 114
San Diego 110
Florence 109
Dong Ket 95
Milan 90
São Paulo 89
London 84
San Mateo 84
Shanghai 84
Tokyo 72
Shenyang 71
Abuja 67
Málaga 67
Chennai 66
Orem 66
Chicago 64
Rome 63
Tianjin 60
Warsaw 59
Hebei 54
Izmir 53
Düsseldorf 52
Changsha 51
Turku 50
Frankfurt am Main 49
Da Nang 48
Ottawa 48
Columbus 46
Hangzhou 45
Kunming 45
Montreal 43
Guangzhou 41
Redondo Beach 40
Norwalk 39
Brussels 38
Fremont 36
Jiaxing 36
Rio de Janeiro 36
Washington 36
Jinan 35
San Francisco 35
Brno 32
Haiphong 32
Toronto 32
Catania 31
Nuremberg 31
Bengaluru 30
Denver 30
Gavirate 30
Poplar 30
Amsterdam 29
Brooklyn 29
Belo Horizonte 28
Manchester 27
Stockholm 27
Phoenix 26
Seongnam 26
Venezia 26
Zhengzhou 26
Abidjan 25
Boston 25
Redwood City 25
Totale 27.092
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.039
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 567
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients 443
null 398
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 388
Cytokine modulators in the treatment of sarcoidosis 380
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 351
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 349
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 305
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 287
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 287
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 278
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 272
Exhaled nitric oxide in interstitial lung diseases 271
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 271
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 268
Asbestos exposure assessment by mineralogical analysis of bronchoalveolar lavage fluid 267
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 261
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 261
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 260
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 260
A difficult case: sarcoidosis with CNS involvement or sarcoidosis associated with multiple sclerosis? 259
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 258
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 256
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 256
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 252
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 249
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 249
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 245
Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients 243
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 243
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 243
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 242
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 240
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 239
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 238
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 237
Serum amyloid A in patients with idiopathic pulmonary fibrosis 236
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 235
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 235
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 234
A functional proteomics approach to the comprehension of sarcoidosis 232
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 232
Chitotriosidase activity in patients with interstitial lung disesaes 227
Adaptive immune responses in primary cutaneous sarcoidosis 225
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 223
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 223
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 222
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 222
2D electrophoretic maps of BAL proteins in fibrosing lung diseases 220
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 219
Bone ultrasonography in glucocorticoid induced osteoporosis 218
Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis 217
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 217
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 216
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 215
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 215
Analysis of alveolar and peripheral CD45RO+ T-lymphocytes in sarcoidosis 214
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease 214
Abnormalities in calcium metabolism in sarcoidosis 213
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 212
The analysis of tryptase in serum of sarcoidosis patients 211
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 211
Proteome analysis of bronchoalveolar lavage in lung diseases 210
Quality of life, anxiety and depression in Sarcoidosis 210
Assessment of cardiac involvement in sarcoidosis by echocardiography 210
The pharmacological treatment of bronchiectasis 209
Phenotypes of organ involvement in sarcoidosis 209
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 208
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial 207
A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis. 207
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 205
Serum analysis of coagulation factors in IPF and NSIP 203
Severe acute graft versus host disease after lung transplant: report of a case successfully treated with high dose corticosteroids 202
Postoperative acute kidney injury in lung transplant recipients 202
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 202
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors 201
Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement 201
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 201
Serum amyloid A: A potential biomarker of lung disorders 201
Extracorporeal Photopheresis in Lung Transplantation 200
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 199
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 199
Chitotriosidase: a sensitive biomarker of sarcoidosis 198
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 197
Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study 197
Proteomic investigation of pulmonary sarcoidosis 197
Doubts and certainness in diagnosis of pulmonary embolism in the elderly 195
Effects of calcitriol on IFN-gamma production by alveolar and peripheral lymphocytes of patients with sarcoidosis. 195
Sarcoidosis with upper respiratory tract involvement 193
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 193
Biomarkers in sarcoidosis: The contribution of system biology 193
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 191
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 191
Gardening in greenhouses as a risk factor for silicosis. 189
Concentrations of major elements and mercury in unstimulated human saliva 188
IPF mortality in waiting list for lung transplantation 188
Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome 183
Pollen grain viability in Parietaria judaica L. during the long blooming period and correlation with meteorological conditions and allergic diseases 179
Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease 179
Totale 24.502
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.988
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.988
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021931 0 0 0 0 0 0 0 0 0 315 316 300
2021/20222.687 202 387 146 219 127 71 122 124 119 291 311 568
2022/20233.957 295 344 489 589 389 774 78 318 394 95 127 65
2023/20242.810 136 59 231 100 102 760 968 71 17 73 52 241
2024/20255.380 147 296 559 289 689 279 159 271 383 260 624 1.424
2025/202611.763 1.053 1.713 1.536 1.499 2.424 551 1.535 369 421 662 0 0
Totale 41.343